Drug Trial Radar · NCT01071876
BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS
Last checked: Nov 19, 2026Latest source record: Jan 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
244
Actual
Start
Aug 2011
Primary completion
Mar 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- BioprojetAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 19, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter randomized double blind study versus placebo during 12 weeks with at first, an escalating dose period followed by stable dose period at the selected dose. This double-blind period can be followed by a 9 months open-label period if the patient wishes to continue with the study product.
Conditions
- Obstructive Sleep Apnea
- Excessive Daytime Sleepiness
Interventions
BF2.649Drug
1 capsule in the morning before breakfast
PlaceboDrug
1 capsule in the morning before breakfast
Primary outcomes
What the sponsor says the trial is designed to measure.
- ESS change (Epworth Sleepiness Scale)Time frame: at week 12 /52 versus baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Grenoble
Grenoble, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.